Compagnie Lombard Odier SCmA Sells 8,018 Shares of Moderna, Inc. (NASDAQ:MRNA)

Compagnie Lombard Odier SCmA lessened its holdings in shares of Moderna, Inc. (NASDAQ:MRNA) by 6.2% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 120,286 shares of the company’s stock after selling 8,018 shares during the quarter. Compagnie Lombard Odier SCmA’s holdings in Moderna were worth $5,001,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Blue Trust Inc. grew its stake in shares of Moderna by 365.6% in the 3rd quarter. Blue Trust Inc. now owns 731 shares of the company’s stock worth $49,000 after acquiring an additional 574 shares in the last quarter. Wilmington Savings Fund Society FSB lifted its position in shares of Moderna by 295.0% during the fourth quarter. Wilmington Savings Fund Society FSB now owns 786 shares of the company’s stock valued at $33,000 after purchasing an additional 587 shares in the last quarter. Larson Financial Group LLC lifted its position in shares of Moderna by 53.5% during the third quarter. Larson Financial Group LLC now owns 910 shares of the company’s stock valued at $61,000 after purchasing an additional 317 shares in the last quarter. Rakuten Securities Inc. lifted its position in shares of Moderna by 477.3% during the third quarter. Rakuten Securities Inc. now owns 941 shares of the company’s stock valued at $63,000 after purchasing an additional 778 shares in the last quarter. Finally, MassMutual Private Wealth & Trust FSB lifted its position in shares of Moderna by 58.2% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 1,057 shares of the company’s stock valued at $44,000 after purchasing an additional 389 shares in the last quarter. Institutional investors own 75.33% of the company’s stock.

Insider Buying and Selling at Moderna

In other Moderna news, insider Shannon Thyme Klinger sold 1,418 shares of Moderna stock in a transaction that occurred on Friday, November 29th. The shares were sold at an average price of $42.79, for a total transaction of $60,676.22. Following the completion of the sale, the insider now directly owns 19,717 shares in the company, valued at $843,690.43. The trade was a 6.71 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders sold a total of 2,664 shares of company stock worth $115,210 over the last three months. 15.70% of the stock is owned by insiders.

Analyst Ratings Changes

MRNA has been the topic of a number of recent analyst reports. Hsbc Global Res raised shares of Moderna from a “hold” rating to a “strong-buy” rating in a research report on Monday, November 18th. UBS Group dropped their price target on shares of Moderna from $108.00 to $96.00 and set a “buy” rating on the stock in a research report on Wednesday, January 8th. Berenberg Bank raised their price target on shares of Moderna from $33.00 to $42.00 and gave the company a “hold” rating in a research report on Thursday, January 16th. Evercore ISI dropped their price target on shares of Moderna from $60.00 to $50.00 and set an “in-line” rating on the stock in a research report on Monday, January 27th. Finally, Leerink Partners lowered their price objective on shares of Moderna from $31.00 to $27.00 and set an “underweight” rating on the stock in a research report on Thursday, January 16th. Four equities research analysts have rated the stock with a sell rating, fourteen have given a hold rating, four have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Moderna currently has an average rating of “Hold” and a consensus price target of $66.89.

Moderna Stock Performance

Shares of NASDAQ:MRNA opened at $31.92 on Friday. The company has a 50 day moving average of $39.31 and a 200 day moving average of $55.94. Moderna, Inc. has a 12 month low of $30.24 and a 12 month high of $170.47. The company has a quick ratio of 4.20, a current ratio of 4.39 and a debt-to-equity ratio of 0.05.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.